Sound Bioventures
Sound Bioventures is a Scandinavian venture capital fund investing in clinical-stage private biotech companies in Europe and the USA developing novel medicines for unmet medical needs, with €116M in Fund I capital deployed across ten portfolio companies.
- Company typePrivate
- Founded2021
- HeadquartersMalmö, Sweden
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Sound Bioventures does
Sound Bioventures is a Scandinavian venture capital fund founded in January 2022 and headquartered in Malmö, Sweden, with additional offices in Stockholm, Hellerup (Copenhagen, Denmark) and Bethesda, Maryland. The firm invests in about-to-be-clinical and clinical-stage private biotech companies across Europe and the USA that are developing novel medicines for significant unmet medical needs, with a thematic focus on specialty therapeutics including orphan and rare diseases. Fund I held a first close at €110 million in January 2022 anchored by Novo Holdings, Saminvest, Vækstfonden, the European Investment Fund and Ramsbury Invest, and has been built up to approximately €116 million; all portfolio companies have reached clinical stage. The portfolio spans 10-11 companies across oncology (Cytospire Therapeutics, Theolytics), cardiovascular (AnaCardio), autoimmune (Artax Biopharma, Aboleris), neurodegenerative disease (Teitur Trophics), ophthalmology (Breye Therapeutics), RNA therapeutics (ARTHEx Biotech), rare pediatric skeletal disease (BOOST Pharma), renal disease (NephroDI) and coagulation (VarmX).
The firm operates a direct, sales-led investment model: deal flow is sourced through trans-Atlantic networking, biotech partnering conferences, the firm's investment proposal portal ([email protected]) and company-creation activities led by its Entrepreneur-in-Residence. Sound Bioventures typically co-invests alongside specialist life science syndicates (4BIO Capital, Sunstone, Industrifonden, Bpifrance, Abingworth, LifeArc, Servier Ventures, British Business Bank, Criteria Bio Ventures) and takes board seats for active portfolio management. The two Managing Partners — Casper Breum (ex-Novo Nordisk, Lundbeck, Lundbeckfonden Ventures) and Johan Kördel (Ph.D., ex-Pharmacia, Biovitrum, Lundbeckfonden Ventures) — are supported by five investment professionals across the Copenhagen, Stockholm and US offices.
Revenue is generated through a standard fund-management economic model: recurring management fees on committed/invested Fund I capital plus carried interest on successful exits. Pricing and carried interest terms are not publicly disclosed. The most significant value-creation event to date is the September 2025 strategic collaboration between portfolio company VarmX and CSL Behring for VMX-C001 (a DOAC reversal agent), valued at up to $2.1 billion in upfront, development and commercial milestone payments approximately 34 months after Sound Bioventures' initial investment. No portfolio company has yet achieved a completed IPO or trade-sale exit, so realized carried interest has not been reported.
Sound Bioventures firmographics
Firmographics- Name
- Sound Bioventures
- Legal name
- Sound Bioventures Management AB
- Website
- https://soundbioventures.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Sound Bioventures is a Scandinavian venture capital fund investing in clinical-stage private biotech companies in Europe and the USA developing novel medicines for unmet medical needs, with €116M in Fund I capital deployed across ten portfolio companies.
- Ownership category
- akta.pro rank
Where Sound Bioventures is headquartered
LocationHeadquarters
- HQ city
- Malmö
- HQ country
- Sweden
- HQ region
- Europe
Offices4 records
Markets served
Sound Bioventures business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Others
Revenue model
- Fund Management: Venture capital fund generating returns through equity investments in portfolio companies, with revenue derived from fund management fees and carried interest on successful investments
- Portfolio Company Returns: Returns realized through exits via M&A transactions (e.g., VarmX partnership with CSL Behring valued up to $2.1B) or IPOs
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Sound Bioventures product offering
Product offeringCore offering
Sound Bioventures manages a venture capital fund (Fund I) that invests equity capital into about-to-be-clinical and clinical-stage private biotech companies across Europe and the USA. The firm supports these portfolio companies through syndicate participation, co-investment, board representation, and company creation, targeting novel medicines for significant unmet medical needs in specialty therapeutic areas.
Product overview
Sound Bioventures is a venture capital fund that operates as a single unified investment vehicle (Fund I) rather than a platform-plus-modules architecture. The fund invests in about-to-be clinical and clinical stage private biotech companies across Europe and USA. The portfolio consists of 11 portfolio companies focused on developing novel medicines addressing significant unmet medical needs across specialty therapeutic areas including oncology (Cytospire Therapeutics, Theolytics), rare pediatric diseases (BOOST Pharma, NephroDI), heart failure (AnaCardio), autoimmune diseases (Artax Biopharma, Aboleris), neurodegenerative diseases (Teitur Trophics), ophthalmology (Breye Therapeutics), RNA medicines (ARTHEx Biotech), and coagulation disorders (VarmX).
Differentiator
Problem solved
Functional benefit
Products and services
- Sound Bioventures Fund I A venture capital fund investing equity capital into about-to-be-clinical and clinical-stage private biotech companies in Europe and the USA developing medicines in specialty therapeutics areas with significant unmet medical needs. Closed at €116M (first close €110M in January 2022), anchored by Novo Holdings, Saminvest, Vækstfonden, EIF, and Ramsbury Invest.
Quantifiable outcome
- Fund I raised €116M from leading institutional investors and family offices
- +2 more outcomes
Companies that use Sound Bioventures
Customer profileNamed customers11 records
Segments2 records
Ideal customer profiles1 record
Sound Bioventures technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Sound Bioventures partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- CSL BehringcoreStrategic collaboration with VarmX to fully fund Phase III program for VMX-C001; up to $2.1B in upfront, development, and commercial milestone payments
Scale indicators5 records
Recent moves7 records
Expansion highlights5 records
Sound Bioventures competitors and assessment
Company assessmentDirect peers
- Novo Seeds: Early-stage life sciences venture arm of Novo Holdings, also based in the Nordics and focused on clinical-stage biotech. Directly comparable to Sound Bioventures in geography, stage focus, and therapeutic specialization, and a co-investor (anchored Fund I).
- Lundbeckfonden Ventures: Copenhagen-based life sciences VC and the prior employer of several Sound Bioventures team members. Invests in clinical-stage European biotech with Nordic roots, making it one of the closest direct competitors.
- Sunstone Life Science Ventures: Danish/European early-stage life sciences VC investing in Series A clinical-stage biotech. Co-led Teitur Trophics' Series A with Sound Bioventures, illustrating overlapping deal sourcing and stage focus.
- Industrifonden: Swedish venture capital firm with a strong life sciences practice that has co-invested with Sound Bioventures (e.g., Teitur Trophics Series A). Comparable Nordic footprint and clinical-stage therapeutic focus.
- HealthCap: Stockholm-based venture capital firm focused exclusively on life sciences, investing in clinical and growth-stage European biotech. Direct competitor in the Nordic clinical-stage VC market.
- BioGeneration Ventures: Dutch early-stage life sciences VC focused on clinical-stage biotech company creation in Europe. Comparable in fund size, stage focus, and company-creation model.
- Gilde Healthcare: European healthcare VC investing across biotech and medtech with multiple funds. Overlapping thesis on clinical-stage biotech and similar mid-sized fund vintages.
- INKEF Capital: Dutch life sciences and technology VC investing from Series A onwards in clinical-stage biotech. Comparable in stage, geography, and Nordic/European cross-border mandate.
- 4BIO Capital: UK-based life sciences VC specialized in cell and gene therapies. Co-led the Cytospire Therapeutics Series A with Sound Bioventures participation, demonstrating overlapping clinical-stage deal flow.
Broad incumbents
- Forbion: Large European life sciences VC manager with multiple funds and broader geographic reach. While operating at a larger scale, it competes for the same clinical-stage biotech deals across Europe and the US.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
Sound Bioventures social profiles
Digital presenceSound Bioventures financial estimates
Financial estimateRevenue estimate
Valuation estimate
Sound Bioventures leadership team
Management profileNumber of profiles
Profiles10 records
Sound Bioventures funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Sound Bioventures M&A and investment
M&A and investmentM&A
Investments13 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Sound Bioventures
What does Sound Bioventures do?
Sound Bioventures manages a venture capital fund (Fund I) that invests equity capital into about-to-be-clinical and clinical-stage private biotech companies across Europe and the USA. The firm supports these portfolio companies through syndicate participation, co-investment, board representation, and company creation, targeting novel medicines for significant unmet medical needs in specialty therapeutic areas.
Is Sound Bioventures a public or private company?
Sound Bioventures is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Sound Bioventures founded?
Sound Bioventures was founded in 2021. It employs 1 to 10 people.
Where is Sound Bioventures based?
Sound Bioventures is headquartered in Malmö, Sweden, in the Europe region.
How does Sound Bioventures make money?
Two revenue lines are on record. Fund Management is the primary driver. The others are portfolio Company Returns.
Who are Sound Bioventures's main competitors?
Direct peers on record are Novo Seeds, Lundbeckfonden Ventures, Sunstone Life Science Ventures, Industrifonden, HealthCap, BioGeneration Ventures, Gilde Healthcare, INKEF Capital and 4BIO Capital. Forbion is listed as a broad incumbent.
Does Sound Bioventures have an API?
No public API is recorded for Sound Bioventures.